免疫检查点抑制剂相关性肺炎的风险因素和预后

打开文本图片集

【中图分类号】R392.1；R730.51【文献标志码】A【收稿日期】2025-01-06

Risk factors and prognosis of checkpoint inhibitor pneumonitis

Xie Hongl，Wang Jun² （1. School of Clinical Medicine，Shandong Second Medical University;2.Department of Oncology， TheFirst Affiliated Hospital ofShandong First Medical University）

【AbstractImmunecheckpointinhibitors（ICIs）havebeenwidelyusedinthetreatmentofadvancedsolidtumorsandhavebrought goodclinicalbenefits.However，hileICIscanactivateimmuneresponseintheodytoexertanantitumorfect，teycanalsocause inflammatoryrsponseinultipleogansstemstroughoutthebodynownasimmunrelateddverseevents（iAEs）.Cnt inhibitorpneumonitis（CI）isoneofsevereirAEs，hichcanafectthfcacyofimmunotherapyandvenbelife-threateningere fore，identifingteiskfctorsforCndexploingeatedpreditiemarkersaeofgeatimporaceforeprtreamsesmentand whole-course monitoringandtreatmentofpatints withsolidtumorsreceivingICIs.Thisarticlesummarzes theresearchadvancesinCdingiideceateiscors，eamnt，dprgosisdissetomakersfoealg mentand prediction of CIP，in order to provide areferencefor clinical diagnosis and mechanism studies.

【Keywordslimmunotherapy;mmunecheckpointinhibitors;mmune-relatedadverseevents;heckpointinibitorpneumoiis;sk factors;biomarkers;diagnosis

作者介绍：谢虹，Email：2274653089@qq.com，研究方向：实体瘤免疫治疗。（剩余28742字）